Receptor Binding & Signalling: How Peptides Trigger Biological Responses
A comprehensive exploration of peptide-receptor interactions, signal transduction pathways, and the molecular mechanisms that translate receptor binding into physiological effects.
Introduction to Receptor Biology
Receptors are specialised protein structures that serve as the primary interface between signalling molecules and cellular responses. They are the biological "locks" that peptide "keys" must fit to initiate physiological effects. Understanding receptor biology is fundamental to comprehending how peptides—and indeed all signalling molecules—exert their actions.
When a peptide binds to its cognate receptor, it induces a conformational change in the receptor protein. This structural alteration triggers a cascade of intracellular events known as signal transduction, ultimately resulting in changes to cellular behaviour—whether that's gene expression, metabolic activity, secretion, or motility.
The Receptor-Ligand Interaction
Signalling molecule
Membrane protein
Activated state → Signal transduction
The binding is typically reversible and governed by the law of mass action. Key parameters include binding affinity (how tightly the ligand binds) and dissociation constant (Kd)—lower Kd values indicate higher affinity.
Key Concepts
- Selectivity: Receptors preferentially bind specific ligands over others, determined by complementary molecular shapes and chemical properties
- Saturation: At high ligand concentrations, all receptors become occupied, reaching maximum response (Emax)
- Desensitisation: Prolonged receptor activation can lead to reduced responsiveness through mechanisms like receptor internalisation or phosphorylation
- Constitutive Activity: Some receptors exhibit baseline activity even without ligand binding, which can be suppressed by inverse agonists
Receptor Types & Classifications
Receptors are classified based on their structure, location, and signal transduction mechanisms. The majority of peptide receptors fall into two major categories: G protein-coupled receptors (GPCRs) and receptor tyrosine kinases (RTKs), though peptides can also interact with other receptor types.
| Receptor Type | Structure | Signal Mechanism | Peptide Examples |
|---|---|---|---|
| GPCRs | 7-transmembrane domains | G proteins → second messengers | GLP-1, Ghrelin, Oxytocin |
| Receptor Tyrosine Kinases | Single transmembrane, kinase domain | Autophosphorylation → kinase cascades | Insulin, IGF-1 |
| Cytokine Receptors | Multimeric, no intrinsic kinase | JAK-STAT pathway | Erythropoietin, GH |
| Ligand-Gated Ion Channels | Multimeric pore-forming | Ion flux | Some neuropeptides |
| Intracellular Receptors | Nuclear/cytoplasmic | Direct transcription regulation | Rare for peptides |
Clinical Significance
GPCRs are the most important class of receptors for peptide therapeutics. Approximately 34% of all FDA-approved drugs target GPCRs, making them the single largest target class in pharmacology. Many research peptides, including growth hormone secretagogues like Ipamorelin and GHRP-6, act through GPCRs.
G Protein-Coupled Receptors (GPCRs)
GPCRs represent the largest superfamily of cell surface receptors in the human genome, with over 800 members. They are characterised by their distinctive seven-transmembrane domain structure, with an extracellular N-terminus and intracellular C-terminus.
GPCR Structure & Activation
═══════════════ Cell Membrane ═══════════════
Extracellular Domain
- • N-terminus
- • Extracellular loops (ECL1-3)
- • Ligand binding pocket
Intracellular Domain
- • C-terminus
- • Intracellular loops (ICL1-3)
- • G protein coupling site
Activation Mechanism
- 1. Ligand binding: Peptide binds to extracellular/transmembrane pocket
- 2. Conformational change: Receptor shifts to active conformation
- 3. G protein activation: GDP exchanged for GTP on α subunit
- 4. Subunit dissociation: Gα separates from Gβγ complex
- 5. Effector activation: Both subunits activate downstream effectors
G Protein Types
| G Protein | Primary Effector | Second Messenger | Example Peptide Receptors |
|---|---|---|---|
| Gαs | Adenylyl cyclase ↑ | cAMP ↑ | GLP-1R, GHRHR, Glucagon-R |
| Gαi/o | Adenylyl cyclase ↓ | cAMP ↓ | Somatostatin-R, Opioid-R |
| Gαq/11 | Phospholipase C ↑ | IP3, DAG, Ca²⁺ | GnRH-R, Oxytocin-R, GHSR |
| Gα12/13 | RhoGEF | Rho activation | Some chemokine receptors |
Ligand-Receptor Specificity
The specificity of peptide-receptor interactions is determined by complementary structural features at the molecular interface. This "lock and key" mechanism, refined to "induced fit" in modern understanding, ensures that only appropriate ligands activate specific receptors.
Structural Determinants
- Shape complementarity: Three-dimensional fit between ligand and binding pocket
- Hydrogen bonding: Specific H-bond donor/acceptor pairs
- Electrostatic interactions: Charged amino acid pairing
- Hydrophobic contacts: Non-polar residue interactions
Binding Parameters
- Kd (Dissociation constant): Concentration at 50% receptor occupancy
- Kon (Association rate): Speed of ligand-receptor binding
- Koff (Dissociation rate): Speed of ligand-receptor separation
- Residence time: Duration ligand remains bound (1/Koff)
Example: Growth Hormone Secretagogue Receptor (GHSR)
The GHSR (ghrelin receptor) illustrates ligand specificity. While ghrelin is the endogenous ligand, synthetic peptides vary dramatically in their selectivity:
| Peptide | GHSR Activity | Selectivity Profile |
|---|---|---|
| Ghrelin (endogenous) | Full agonist | GHSR selective |
| Ipamorelin | Selective agonist | Highly GHSR selective, minimal cortisol/prolactin |
| GHRP-6 | Potent agonist | Less selective, increases appetite |
| Hexarelin | Potent agonist | Additional cardiac effects, some cortisol elevation |
Signal Transduction Pathways
Signal transduction is the process by which extracellular signals are converted into intracellular responses. This involves a cascade of molecular events that amplify and transmit the signal from the receptor to effector molecules within the cell.
Signal Amplification Cascade
Major Signalling Pathways
cAMP/PKA Pathway
Activated by Gαs-coupled receptors. Adenylyl cyclase converts ATP to cyclic AMP (cAMP), which activates Protein Kinase A (PKA). PKA phosphorylates target proteins including CREB transcription factor.
Example peptides: GLP-1 (incretin effect), GHRH (GH secretion), glucagon (glycogenolysis)
PLC/IP3/DAG Pathway
Activated by Gαq-coupled receptors. Phospholipase C cleaves PIP2 into IP3 (releases Ca²⁺ from ER) and DAG (activates Protein Kinase C). Results in rapid calcium signalling and PKC-mediated phosphorylation.
Example peptides: Ghrelin (appetite/GH release), oxytocin (uterine contraction), GnRH (LH/FSH release)
MAPK/ERK Pathway
Mitogen-Activated Protein Kinase cascade. Activated by RTKs (insulin, IGF-1) or via GPCR β-arrestin signalling. Ras → Raf → MEK → ERK cascade leads to gene transcription and cell proliferation.
Example peptides: Insulin (metabolic effects), IGF-1 (growth), growth factors
JAK-STAT Pathway
Janus Kinase-Signal Transducer and Activator of Transcription. Cytokine receptors activate JAKs, which phosphorylate STATs. STATs dimerise and translocate to nucleus for direct transcriptional regulation.
Example peptides: Growth hormone (via GH receptor), erythropoietin, prolactin
Second Messenger Systems
Second messengers are small, rapidly diffusible molecules that relay signals from receptors to target molecules within the cell. They enable signal amplification and integration of multiple inputs, serving as critical nodes in cellular signalling networks.
| Second Messenger | Generated By | Primary Targets | Key Effects |
|---|---|---|---|
| cAMP | Adenylyl cyclase | PKA, EPAC, cyclic nucleotide-gated channels | Gene expression, metabolism, secretion |
| Ca²⁺ | IP3R, voltage-gated channels | Calmodulin, PKC, CaMKII | Contraction, secretion, synaptic transmission |
| IP3 | Phospholipase C | IP3 receptors (ER) | Ca²⁺ release from stores |
| DAG | Phospholipase C | Protein Kinase C | Phosphorylation cascades |
| cGMP | Guanylyl cyclase | PKG, PDEs, CNG channels | Vasodilation, phototransduction |
| PIP3 | PI3 Kinase | Akt/PKB, PDK1 | Cell survival, growth, metabolism |
Calcium as a Universal Signal
Calcium ions (Ca²⁺) serve as perhaps the most versatile second messenger. Resting cytosolic Ca²⁺ is maintained at ~100 nM, roughly 10,000-fold lower than extracellular concentrations. This steep gradient enables rapid, high-amplitude signalling when channels open. Calcium signals are decoded by their amplitude, duration, frequency (oscillations), and spatial localisation.
Agonists, Antagonists & Modulators
Understanding the different types of receptor ligands is essential for interpreting peptide pharmacology. Ligands are classified by their effect on receptor activity, not just their binding properties.
Full Agonists
Bind to receptor and produce maximum possible response (100% efficacy).
Examples: Ghrelin at GHSR, insulin at insulin receptor
Partial Agonists
Bind and activate receptor but produce sub-maximal response even at full receptor occupancy.
Examples: Some synthetic GH secretagogues, certain opioid peptides
Antagonists
Bind to receptor but do not activate it. Block agonist binding, preventing activation.
Examples: GnRH antagonists (degarelix), somatostatin analogues
Inverse Agonists
Bind to receptor and reduce constitutive (baseline) activity below resting levels.
Examples: Some GHSR ligands can act as inverse agonists
Allosteric Modulators
Allosteric modulators bind to a site distinct from the orthosteric (primary) binding site and modify receptor function indirectly.
Positive Allosteric Modulators (PAMs)
Enhance the effect of endogenous ligands without activating the receptor directly. Can increase affinity, efficacy, or both.
Negative Allosteric Modulators (NAMs)
Reduce the effect of endogenous ligands. Decrease receptor sensitivity to orthosteric agonists.
Key Peptide Signalling Pathways
Several peptide signalling pathways are of particular interest in biomedical research. Understanding these pathways provides insight into how therapeutic peptides exert their effects and why certain peptides are researched for specific conditions.
GLP-1 Receptor Signalling
Glucagon-like peptide-1 (GLP-1) is an incretin hormone released from intestinal L-cells in response to food intake. GLP-1 receptor agonists are among the most successful peptide therapeutics.
Signalling Cascade
| Tissue | GLP-1R Effect |
|---|---|
| Pancreatic β-cells | Glucose-dependent insulin secretion, β-cell proliferation |
| Pancreatic α-cells | Reduced glucagon secretion |
| Brain (hypothalamus) | Reduced appetite, increased satiety |
| Stomach | Delayed gastric emptying |
| Heart | Cardioprotective effects (under investigation) |
Growth Hormone Secretagogue Pathway
The GH secretagogue receptor (GHSR) mediates the effects of ghrelin and synthetic growth hormone-releasing peptides. This pathway is central to understanding peptides like Ipamorelin, GHRP-2, and Hexarelin.
Dual Signalling
Gαq/11 Pathway
GHSR → PLC → IP3 + DAG → Ca²⁺ release → GH secretion
Gαi/o Pathway (partial)
Modulates cAMP, contributes to receptor signalling complexity
Key insight: Different synthetic GH secretagogues exhibit varying degrees of selectivity for GH release vs. other GHSR-mediated effects (appetite, cortisol, prolactin). Ipamorelin's selectivity is attributed to its specific receptor interaction pattern that preferentially activates GH-releasing pathways.
GIP Receptor Signalling
Glucose-dependent insulinotropic polypeptide (GIP) is another incretin hormone, working synergistically with GLP-1. Dual GLP-1/GIP agonists represent an advanced approach in metabolic peptide therapeutics.
| Feature | GLP-1R | GIPR |
|---|---|---|
| Primary G protein | Gαs | Gαs |
| Insulin secretion | Glucose-dependent ↑ | Glucose-dependent ↑ |
| Appetite | Strong suppression | Modest effect |
| Adipose tissue | Limited direct effect | Lipid storage, adipogenesis |
| Bone | Positive effects reported | Promotes bone formation |
Further Reading
Educational Content Disclaimer
This article is provided for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. The molecular mechanisms described represent current scientific understanding and may be refined as research advances.
UK & EU Context: Many peptides discussed are research compounds not approved for human therapeutic use. Always consult qualified healthcare professionals and adhere to applicable regulations in your jurisdiction.